ALEXANDER MARGARET A. 4

What Happened
Margaret A. Alexander, President & CEO and a director of Ovid Therapeutics (OVID), had two transactions reported. On 2026-02-23 she disposed of 11,656 shares in a sell-to-cover transaction for approximately $16,901 (weighted avg ~$1.45). On 2026-02-26 she was granted/acquired a derivative award covering 1,435,000 shares at $0.00 (no cash paid at grant).

Key Details

• Sale: 11,656 shares sold on 2026-02-23; weighted average price reported $1.45 (sales ranged $1.45–$1.48); total proceeds ~$16,901. Footnote: this was a mandatory "sell to cover" to satisfy tax withholding (not a discretionary sale).
• Award/Derivative: 1,435,000 shares reported as acquired on 2026-02-26 at $0.00 (derivative/option grant).
• Vesting: The award/option vests in 48 equal monthly installments beginning March 20, 2026, subject to continued service.
• Shares owned after transaction: Not specified in the provided excerpt—see the full Form 4 for final ownership totals.
• Filing timeliness: Transaction date 2/23/2026; Form 4 filed 3/02/2026 — this filing was submitted after the typical 2‑business‑day window (i.e., filed late).

Context

• The small sale was a routine sell-to-cover for tax withholding tied to vesting; it should not be read as a discretionary bearish signal.
• The large 1.435M‑share entry is a derivative grant (likely a stock option or restricted award) that vests monthly, meaning the economic benefit is realized over time and is contingent on continued service.